Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.

Meletios A. Dimopoulos,Ivan Spicka,Hang Quach,Albert Oriol,Roman Hájek,Mamta Garg,Meral Beksac,Sara Bringhen,Eirini Katodritou,Wee Joo Chng,Xavier Leleu,Shinsuke Iida,Maria-Victoria Mateos,Gareth J. Morgan,Alexander Vorog,Richard Labotka,Bingxia Wang,Antonio Palumbo,Sagar Lonial

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.

2020

Meletios A. Dimopoulos
Ivan Spicka
Hang Quach
Albert Oriol
Roman Hájek
Mamta Garg
Meral Beksac
Sara Bringhen
Eirini Katodritou
Wee Joo Chng
Xavier Leleu
Shinsuke Iida
Maria-Victoria Mateos
Gareth J. Morgan
Alexander Vorog
Richard Labotka
Bingxia Wang
Antonio Palumbo
Sagar Lonial

PURPOSEMaintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has gener...

Keywords:

Oncology
Ixazomib
Multiple myeloma
Internal medicine
in patient
Autologous stem-cell transplantation
newly diagnosed
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations